Raised $2.5 million in seed investment; Won > $6 million in grants from US DoD, NIH, and NSF Huge markets and financial opportunities: 3.1 billion USD tuberculosis & 20 billion USD lung cancer diagnostics in 2022 Our products - low cost, accurate, non-invasive, non-lab dependent lung cancer & tuberculosis tests Our CE Mark is targeted by Q1 2022, allowing product distribution in EU countries; clear path to FDA clinical trials We have a portfolio of proprietary material, filed patents and licensed IPs Each year: 10 million new TB infections & 2 million deaths; 2.1 million new Lung Cancer cases & 2 million new deaths Our TB test is specifically developed to meet all WHO requirements for performance, cost and use British Biocell International (BBI) is our manufacturing partner